Preclinical Investigations With Epothilones in Breast Cancer Models

Seminars in Oncology

Volumn 35, Issue SUPPL. 2, 2008, Pages

  Burris III, Howard A ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BMS 310705; CAPECITABINE; DOXORUBICIN; EPOTHILONE A; EPOTHILONE B; EPOTHILONE D; EPOTHILONE DERIVATIVE; FLUOROURACIL; IXABEPILONE; KOS 1584; KS 862; PACLITAXEL; UNCLASSIFIED DRUG; ZK 219477; ZK EPO;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; COMPARATIVE STUDY; CYTOTOXICITY; DRUG STRUCTURE; HUMAN; IN VITRO STUDY; MONOTHERAPY; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; CLINICAL TRIALS, PHASE I AS TOPIC; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; EPOTHILONES; FEMALE; FLUOROURACIL; HUMANS; MICE; MICE, NUDE; MICROTUBULES; PACLITAXEL; TUBULIN MODULATORS;

EID: 41849092942     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2008.02.002     Document Type: Article

References (24)

1. Esteva F.J., Valero V., Pusztai L., et al. Chemotherapy of metastatic breast cancer: What to expect in 2001 and beyond. Oncologist 6 (2001) 133-146
2. Seidman A.D. Systemic treatment of breast cancer. Two decades of progress. Oncology (Williston Park) 20 (2006) 983-990
3. Bollag D.M., McQueney P.A., Zhu J., et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 55 (1995) 2325-2333
4. ®). J Biol Chem 272 (1997) 2534-2541
5. Cortes J., and Baselga J. Targeting the microtubules in breast cancer beyond taxanes: The epothilones. Oncologist 12 (2007) 271-280
6. Lee F.Y., Borzilleri R., Fairchild C.R., et al. BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 7 (2001) 1429-1437
7. Chou T.C., O'Connor O.A., Tong W.P., et al. The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: Curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice. Proc Natl Acad Sci U S A 98 (2001) 8113-8118
8. Zhou Y., Zhong Z., Liu F., et al. KOS-1584: A rationally designed epothilone D analog with improved potency and pharmacokinetic (PK) properties. Proc Am Assoc Cancer Res 46 (2005). http://www.aacrmeetingabstracts.org (abstr 2535) Available at: www.aacrmeetingabstracts.org (accessed Nov 7, 2007)
9. Goodin S., Kane M.P., and Rubin E.H. Epothilones: Mechanism of action and biologic activity. J Clin Oncol 22 (2004) 2015-2025
10. Fumoleau P., Coudert B., Isambert N., et al. Novel tubulin-targeting agents: Anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol 18 suppl 5 (2007) v9-v15
11. Chou T.C., Zhang X.G., Balog A., et al. Desoxyepothilone B: An efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. Proc Natl Acad Sci U S A 95 (1998) 9642-9647
12. Fojo T., and Menefee M. Mechanisms of multidrug resistance: The potential role of microtubule-stabilizing agents. Ann Oncol 18 suppl 5 (2007) v3-v8
13. Altmann K.H., Wartmann M., and O'Reilly T. Epothilones and related structures-A new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta 1470 (2000) M79-M91
14. Duran G.E., Jordan M.A., and Sikic B.I. Impaired taxane- and epothilone-driven tubulin polymerization in a non-MDR1 taxane-resistant MCF-7 breast cancer variant with reduced MAP4 and elevated MAP Tau content. Proc Am Assoc Cancer Res 47 (2006). http://www.aacrmeetingabstracts.org (abstr 3755) Available at: www.aacrmeetingabstracts.org (accessed Nov 7, 2007)
15. Lee F.Y., Camuso A., Castenada S., et al. Preclinical studies of ixabepilone (BMS-247550) demonstrate optimal antitumor activity against both chemotherapy-sensitive and -resistant tumor types. Proc Am Assoc Cancer Res 47 (2006). http://www.aacrmeetingabstracts.org (abstr 503) Available at: www.aacrmeetingabstracts.org (accessed Nov 7, 2007)
16. Kamath A.V., Chang M., Lee F.Y., et al. Preclinical pharmacokinetics and oral bioavailability of BMS-310705, a novel epothilone B analog. Cancer Chemother Pharmacol 56 (2005) 145-153
17. Sessa C., Perotti A., Lladò A., et al. Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule. Ann Oncol 18 (2007) 1548-1553
18. Hoffmann J., Buchmann B., Schwede W., et al. New synthetic epothilone derivative ZK-EPO inhibits breast cancer metastasis. Proc Am Assoc Cancer Res 46 (2005). http://www.aacrmeetingabstracts.org (abstr 3424) Available at: www.aacrmeetingabstracts.org (accessed Nov 7, 2007)
19. Klar U., Buchmann B., Schwede W., et al. ZK-EPO, a novel synthetic epothilone B analog, significantly inhibits tumor growth in both non-resistant and resistant breast cancer models. Breast Cancer Res Treat 94 suppl 1 (2005) S64 (abstr 1072)
20. Hoffmann J., Winsel S., Hammer S., et al. Activity of the third-generation epothilone ZK-EPO, compared with paclitaxel and other tubulin-binding agents, in the inhibition of breast tumor cell growth and proliferation. Breast Cancer Res Treat 100 suppl 1 (2006) S72 (abstr 1103)
21. Hoffmann J., Fichtner I., and Klar U. ZK-EPO, a potent third-generation epithilone, is effective in models of breast cancer metastasis. Proc Am Assoc Cancer Res 47 (2006). http://www.aacrmeetingabstracts.org (abstr 511) Available at: www.aacrmeetingabstracts.org (accessed Nov 7, 2007)
22. Chou T.C., Zhang X.G., Harris C.R., et al. Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. Proc Natl Acad Sci U S A 95 (1998) 15798-15802
23. Zhong Z., Eng S., Craig D., et al. Tissue distribution and pharmacokinetics (PK) for KOS-1584: A rationally designed microtubule polymerization stabilizer. Proc Am Assoc Cancer Res 47 (2006). http://www.aacrmeetingabstracts.org (abstr 3098) Available at: www.aacrmeetingabstracts.org (accessed Nov 7, 2007)
24. Chou T.-C., Zhang X., Dong H., et al. Therapeutic evaluation of the second-generation epothilone, dehydelone, as a microtubule stabilization antitumor agent in xenograft models. Proc Am Assoc Cancer Res 47 (2006). http://www.aacrmeetingabstracts.org (abstr 492) Available at: www.aacrmeetingabstracts.org (accessed Nov 7, 2007)